Showing results (51-60 of 646) with videos related to
Sort By:
Pageof 65
Hematological Oncology|February 14, 2019
Low-dose fludarabine and cyclophosphamide combined with standard dose rituximab (LD-FCR) is an effective and safe regimen for elderly untreated patients with chronic lymphocytic leukemia: The Israeli CLL study group experienceYair Herishanu, Tamar Tadmor, Andrei Braester, et al.Acta Haematologica|September 4, 2023
Accelerated Chronic Lymphocytic Leukemia and Richter Transformation in the Era of Novel AgentsIlana Levy Yurkovski, Tamar TadmorIn Vivo (Athens, Greece)|August 19, 2021
'Catastrophic' Thrombosis in a Young Patient With Acute Myeloid Leukemia Presenting Early in the COVID-19 Pandemic - A Case ReportSarah Matarasso Greenfeld, Tamar TadmorActa Haematologica|August 4, 2025
Approach to hairy-cell leukemia in the new therapeutic era with special emphasis on age and comorbiditiesIlana Levy Yurkovski, Tamar TadmorCytometry. Part B, Clinical Cytometry|July 7, 2015
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patientOla Landgren, Roger G OwenBlood Cancer Discovery|December 4, 2024
Minimal Residual Disease as an Early Endpoint for Accelerated Drug Approval in Myeloma: A RoadmapOla Landgren, Sean M DevlinSeminars in Hematology|April 5, 2026
Targeted immunoPET imaging of multiple myelomaGary A Ulaner, Ola LandgrenClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2017
New Developments in Diagnosis, Prognosis, and Assessment of Response in Multiple MyelomaOla Landgren, S Vincent RajkumarCytometry. Part B, Clinical Cytometry|September 15, 2010
Prevalence, clinical aspects, and natural history of IgM MGUSMary L McMaster, Ola LandgrenHematology/Oncology Clinics of North America|October 3, 2007
New aspects in descriptive, etiologic, and molecular epidemiology of Hodgkin's lymphomaOla Landgren, Neil E CaporasoPageof 65